Drug Type Antibody oligonucleotide conjugates |
Synonyms CGB1001 |
Target |
Action inhibitors, antagonists |
Mechanism DMPK inhibitors(DM1 protein kinase inhibitors), TfR1 antagonists(Transferrin receptor protein 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
RegulationOrphan Drug (United States) |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Myotonic Dystrophy | Clinical | China | 14 Feb 2025 |






